US FDA pauses Gilead trials testing experimental HIV pill combination

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. DPZ
2. NVDA
3. DRS
4. GS
5. BAC
6. ORCL
7. AVAV
8. ACI
9. UNH
10. JPM

Go back to US FDA pauses Gilead trials testing experimental HIV pill combination

FDA clinical hold a 'blow to Gilead Sciences (GILD) HIV pipeline - Oppenheimer

June 10, 2025 11:14 AM EDT

Oppenheimer analyst Hartaj Singh reiterated an Outperform rating and $125.00 price target on Gilead Sciences (NASDAQ: GILD) but said the clinical hold is a 'blow' to the company's HIV pipeline.

The analyst commented, "This morning, Gilead announced that the FDA had put ongoing GS-4182+GS-1720... More